Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Taranabant

Next Previous
X
Search
Drug Profile

Taranabant

Alternative Names: MK-0364

Latest Information Update: 02 Oct 2021

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck & Co
  • Class Amides; Obesity therapies; Pyridines
  • Mechanism of Action Cannabinoid 1 receptor inverse agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Obesity; Psychiatric disorders; Smoking withdrawal

Most Recent Events

  • 03 Oct 2008 Discontinued - Phase-III for Obesity in USA, Australia, Austria, Czech Republic, Denmark, Finland, France, Germany, New Zealand and Sweden (PO)
  • 01 Apr 2008 Interim efficacy and adverse events data from a phase III trial in Obesity presented at the 57th Annual Scientific Session of the American College of Cardiology (ACC-2008) ,
  • 31 Oct 2007 Clinical data presented at the 2007 Annual Meeting of the North American Association for the Study of Obesity (NAASO-2007) added to the adverse events , pharmacokinetics ,,, and Obesity therapeutic trials sections

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top